Shire PLC (SHP) Receives Consensus Recommendation of “Buy” from Brokerages
Shire PLC (LON:SHP) has received a consensus recommendation of “Buy” from the nineteen research firms that are covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is GBX 5,056.67 ($68.57).
A number of brokerages have weighed in on SHP. BNP Paribas reissued an “outperform” rating and set a GBX 4,700 ($63.74) price target on shares of Shire in a research note on Tuesday. Shore Capital reissued a “buy” rating on shares of Shire in a research note on Monday. Liberum Capital reissued a “hold” rating and set a GBX 4,100 ($55.60) price target on shares of Shire in a research note on Monday. Deutsche Bank reissued a “buy” rating and set a GBX 5,000 ($67.81) price target on shares of Shire in a research note on Thursday, January 11th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire in a research note on Wednesday, January 10th.
In other news, insider Dominic Blakemore bought 165 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were acquired at an average cost of GBX 3,790 ($51.40) per share, with a total value of £6,253.50 ($8,480.47).
ILLEGAL ACTIVITY WARNING: “Shire PLC (SHP) Receives Consensus Recommendation of “Buy” from Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/16/shire-plc-shp-receives-consensus-recommendation-of-buy-from-brokerages.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.